• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Neuren Pharmaceuticals

Monday, June 03, 2024
CP
CNS/Neurological
Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases. DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide. Neuren’s second drug candidate, NNZ-2591, is in Phase 2 development for each of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.
Neuren Pharmaceuticals
Company Website: https://www.neurenpharma.com/
Lead Product in Development: NNZ-2591

Exchange

ASX

Ticker

NEU

Company HQ City

Camberwell

Company HQ State

Victoria

Company HQ Country

Australia

CEO/Top Company Official

Jon Pilcher

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS